Severity
Moderate
FDA Devices recall · Reported May 2, 2018
The lower concentration of the RNA panel could cause a NO CALL or FALSE NEGATIVE for the reporting of ROS1 fusion. If a physician relies on a false negative result, crizotinib co…
Life Technologies Corporation recalled Oncomine Dx Target Test, (Model No. A32451), Oncomine Dx Target RNA/DNA Panel (Model No. … - a moderate-severity action.
Oncomine Dx Target Test, (Model No. A32451), Oncomine Dx Target RNA/DNA Panel (Model No. … was recalled by Life Technologies Corporation in May 2, 2018. Reason: The lower concentration of the RNA panel could cause a NO CALL or FALSE NEGATIVE for the reporting of ROS1 fu…. Check the official notice for the remedy. Verify recall #Z-1480-2018 with the FDA Devices before acting.
The recall
Life Technologies Corporation issued this moderate-severity FDA Devices recall-The lower concentration of the RNA panel could cause a NO CALL or FALSE NEGATIVE for the reporting of ROS1 fu….
Sourced from official FDA Devices enforcement records. Verify recall #Z-1480-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Devices action (record #Z-1480-2018) was formally reported on May 2, 2018, with the manufacturer initiating the action on February 8, 2018. It is classified under Moderate severity (Class II), with a current status of Terminated. Life Technologies Corporation is listed as the recalling firm, operating out of Frederick, MD. Federal records list the affected scope as 30.
The documented reason for this recall is: The lower concentration of the RNA panel could cause a NO CALL or FALSE NEGATIVE for the reporting of ROS1 fusion. If a physician relies on a false negative result, crizotinib could be improperly excluded from the pati… Distribution data in the federal record shows the product reached: Distributed to states: AZ, CA, NC, TX, and VA.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 6 from FDA Devices - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 40,861 medical devices recalls on record
Of 88,001 recalls with an agency hazard classification, 19,020 are high severity, 64,468 moderate, and 4,513 low. A further 16,157 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
30
Related Recalls
6
6 from same agency
Oncomine Dx Target Test, (Model No. A32451), Oncomine Dx Target RNA/DNA Panel (Model No. A32441). A qualitative In Vitro Diagnostic test.
The lower concentration of the RNA panel could cause a NO CALL or FALSE NEGATIVE for the reporting of ROS1 fusion. If a physician relies on a false negative result, crizotinib could be improperly excluded from the patient's treatment regimen.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | Z-1480-2018 |
| Date reported | May 2, 2018 |
| Date initiated | February 8, 2018 |
| Recalling firm | Life Technologies Corporation |
| Firm location | Frederick, MD |
| Affected scope | 30 |
| Distribution | Distributed to states: AZ, CA, NC, TX, and VA. |
Profile values are sourced directly from the official FDA Devices enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Devices record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Two federal-filing-derived peer sets for this notice, both outside the same recalling firm and filing state so the neighborhoods are not firm or geographic containment.
Same archive severity grade (Moderate), closest by report date among other firms and states.
Same product category, closest by report date among other firms and states (deduped against the severity set).
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Showing 5 of 40909 other recalls in this category.
Boston Scientific Corporation · 2026-07-29
Boston Scientific Corporation · 2026-07-29
AVID Medical, Inc. · 2026-07-29
Penumbra, Inc. · 2026-07-29
Alphatec Spine, Inc. · 2026-07-29
Compare this recall with FARADRIVE STEERABLE SHEATH CLEAR, used to facilitate access… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Devices, reported May 2, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.